BR112022026874A2 - Substância farmacêutica, uso, método de proteção de um indivíduo e vacina - Google Patents
Substância farmacêutica, uso, método de proteção de um indivíduo e vacinaInfo
- Publication number
- BR112022026874A2 BR112022026874A2 BR112022026874A BR112022026874A BR112022026874A2 BR 112022026874 A2 BR112022026874 A2 BR 112022026874A2 BR 112022026874 A BR112022026874 A BR 112022026874A BR 112022026874 A BR112022026874 A BR 112022026874A BR 112022026874 A2 BR112022026874 A2 BR 112022026874A2
- Authority
- BR
- Brazil
- Prior art keywords
- kda
- ksp37
- individual
- vaccine
- protection
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 3
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 102100023589 Fibroblast growth factor-binding protein 2 Human genes 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 101710094941 Fibroblast growth factor-binding protein 2 Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 210000002381 plasma Anatomy 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00113—Growth factors
- A61K39/001132—Fibroblast growth factors [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Communicable Diseases (AREA)
- Marine Sciences & Fisheries (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ZA202003850 | 2020-07-09 | ||
| ZA202004008 | 2020-07-09 | ||
| PCT/IB2021/056179 WO2022009165A1 (en) | 2020-07-09 | 2021-07-09 | Compositions and methods useful for the prevention and/or treatment of disease in mammals |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022026874A2 true BR112022026874A2 (pt) | 2023-01-24 |
Family
ID=79552952
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022026874A BR112022026874A2 (pt) | 2020-07-09 | 2021-07-09 | Substância farmacêutica, uso, método de proteção de um indivíduo e vacina |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20240091310A1 (https=) |
| EP (1) | EP4178604A4 (https=) |
| JP (1) | JP2023533162A (https=) |
| KR (1) | KR20230038230A (https=) |
| CN (1) | CN115720520A (https=) |
| AU (1) | AU2021304479A1 (https=) |
| BR (1) | BR112022026874A2 (https=) |
| CA (1) | CA3179965A1 (https=) |
| CL (1) | CL2023000073A1 (https=) |
| CO (1) | CO2022019251A2 (https=) |
| IL (1) | IL299661A (https=) |
| MX (1) | MX2023000113A (https=) |
| PE (1) | PE20231554A1 (https=) |
| PH (1) | PH12023550038A1 (https=) |
| WO (1) | WO2022009165A1 (https=) |
| ZA (1) | ZA202213371B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025215561A1 (en) * | 2024-04-09 | 2025-10-16 | Viro-Gen (Pty) Ltd | Plasmid for expression of ksp37 |
| WO2025221871A1 (en) * | 2024-04-16 | 2025-10-23 | The Trustees Of Columbia University In The City Of New York | Expansion, propagation, and modulation of immune cell subsets by peptides |
| WO2025233868A1 (en) * | 2024-05-07 | 2025-11-13 | Viro-Gen (Pty) Ltd | Compounds, compositions and methods for treating, reversing or preventing cancer |
| WO2025233869A1 (en) * | 2024-05-07 | 2025-11-13 | Viro-Gen (Pty) Ltd | Compounds, compositions and methods for treating, reversing or preventing type 2 diabetes mellitus |
-
2021
- 2021-07-09 BR BR112022026874A patent/BR112022026874A2/pt unknown
- 2021-07-09 US US18/004,631 patent/US20240091310A1/en active Pending
- 2021-07-09 AU AU2021304479A patent/AU2021304479A1/en active Pending
- 2021-07-09 CN CN202180042656.8A patent/CN115720520A/zh active Pending
- 2021-07-09 PE PE2022003070A patent/PE20231554A1/es unknown
- 2021-07-09 MX MX2023000113A patent/MX2023000113A/es unknown
- 2021-07-09 CA CA3179965A patent/CA3179965A1/en active Pending
- 2021-07-09 WO PCT/IB2021/056179 patent/WO2022009165A1/en not_active Ceased
- 2021-07-09 PH PH1/2023/550038A patent/PH12023550038A1/en unknown
- 2021-07-09 JP JP2022575231A patent/JP2023533162A/ja active Pending
- 2021-07-09 EP EP21838245.5A patent/EP4178604A4/en active Pending
- 2021-07-09 KR KR1020237004448A patent/KR20230038230A/ko active Pending
- 2021-07-09 IL IL299661A patent/IL299661A/en unknown
-
2022
- 2022-12-09 ZA ZA2022/13371A patent/ZA202213371B/en unknown
- 2022-12-29 CO CONC2022/0019251A patent/CO2022019251A2/es unknown
-
2023
- 2023-01-06 CL CL2023000073A patent/CL2023000073A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023533162A (ja) | 2023-08-02 |
| EP4178604A4 (en) | 2024-07-31 |
| PH12023550038A1 (en) | 2024-03-11 |
| KR20230038230A (ko) | 2023-03-17 |
| WO2022009165A1 (en) | 2022-01-13 |
| IL299661A (en) | 2023-03-01 |
| CA3179965A1 (en) | 2022-01-13 |
| AU2021304479A1 (en) | 2023-01-19 |
| PE20231554A1 (es) | 2023-10-03 |
| MX2023000113A (es) | 2023-03-16 |
| EP4178604A1 (en) | 2023-05-17 |
| ZA202213371B (en) | 2023-11-29 |
| CO2022019251A2 (es) | 2023-03-27 |
| CN115720520A (zh) | 2023-02-28 |
| US20240091310A1 (en) | 2024-03-21 |
| CL2023000073A1 (es) | 2023-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022026874A2 (pt) | Substância farmacêutica, uso, método de proteção de um indivíduo e vacina | |
| JP7458438B2 (ja) | 浮遊病原体および刺激物に対して防御するための組成物および方法 | |
| Kawahara et al. | Consecutive oral administration of Bifidobacterium longum MM‐2 improves the defense system against influenza virus infection by enhancing natural killer cell activity in a murine model | |
| BR112022014578A2 (pt) | Composição e métodos de profiláticos e terapêuticos de rnai para o tratamento de infecção respiratória aguda grave causada pelo novo coronavírus 2019 (2019-ncov) | |
| Traboulsi et al. | The flavonoid isoliquiritigenin reduces lung inflammation and mouse morbidity during influenza virus infection | |
| Chakraborty et al. | Clinical management, antiviral drugs and immunotherapeutics for treating monkeypox. An update on current knowledge and futuristic prospects | |
| Wang et al. | Reactive oxygen species associated immunoregulation post influenza virus infection | |
| Mitzel et al. | Age-enhanced endoplasmic reticulum stress contributes to increased Atg9A inhibition of STING-mediated IFN-β production during Streptococcus pneumoniae infection | |
| BR112022017891A2 (pt) | Métodos para tratar a infecção por coronavírus e lesão pulmonar induzida por inflamação resultante | |
| BR112023000730A2 (pt) | Método para induzir e/ou ativar uma resposta imune, forma de dosagem, kit, vetor, célula hospedeira, partículas do vetor lentiviral pseudotipada e composição imunogênica | |
| Yu et al. | The STING inhibitor C‐176 attenuates osteoclast‐related osteolytic diseases by inhibiting osteoclast differentiation | |
| CN107412260A (zh) | cGAS-STING通路激活剂及其用途 | |
| Don et al. | Dose‐dependent antiviral activity of released‐active form of antibodies to interferon‐gamma against influenza A/California/07/09 (H1N1) in murine model | |
| BR112021026292A2 (pt) | Cistationina beta sintase peguilada para terapia enzimática para tratamento de homocistinúria | |
| WO2022192594A3 (en) | Nucleic acid molecules and vaccines comprising same for the prevention and treatment of coronavirus infections and disease | |
| Gil et al. | Inhalation delivery of interferon-λ-loaded pulmonary surfactant nanoparticles induces rapid antiviral immune responses in the lung | |
| US20250295748A1 (en) | Treatment and prevention of viral infections | |
| CA2787812C (en) | Pan-antiviral peptides for protein kinase inhibition | |
| Mifsud et al. | Generation of adaptive immune responses following influenza virus challenge is not compromised by pre-treatment with the TLR-2 agonist Pam2Cys | |
| Khatri et al. | Brugia malayi abundant larval transcript 2 protein treatment attenuates experimentally-induced colitis in mice | |
| BR112022019601A2 (pt) | Vírus sars-cov-2 inativado, composição farmacêutica ou uma vacina, métodos de preparação da composição ou vacina de sars-cov-2 inativado e de tratamento ou imunização contra uma doença associada à infecção por sars-cov-2, vírus sars-cov-2 isolado, e, ácido nucleico isolado | |
| BR112020004935A2 (pt) | Composição farmacêutica compreendendo um anticorpo que se liga especificamente a n-terminal de lisil-trna sintetase como princípio ativo para prevenção ou tratamento de doença relacionada com migração celular | |
| Kanayama et al. | Enhancement of immunomodulative effect of lactic acid bacteria on plasmacytoid dendritic cells with sucrose palmitate | |
| Nuñez-Ortiz et al. | Immunostimulant properties of full-length and truncated Marinobacter algicola flagellins, and their effects against viral hemorrhagic septicemia virus (VHSV) in trout | |
| WO2021188520A1 (en) | Method and compositions for treating, preventing or limiting the occurrence of viral infection |